# Low-dose Interleukin-2 for Treatment of Systemic Lupus Erythematosus

> **NCT03312335** · PHASE2 · COMPLETED · sponsor: **Onur Boyman, MD** · enrollment: 16 (actual)

## Conditions studied

- Lupus Erythematosus, Systemic

## Interventions

- **DRUG:** Low-dose Aldesleukin (Proleukin®)

## Key facts

- **NCT ID:** NCT03312335
- **Lead sponsor:** Onur Boyman, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-08
- **Primary completion:** 2019-12-23
- **Final completion:** 2019-12-23
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2020-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03312335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03312335, "Low-dose Interleukin-2 for Treatment of Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03312335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*